CSS
ARQT icon

Cubist Systematic Strategies’s Arcutis Biotherapeutics ARQT Stock Holding History

Cubist Systematic Strategies’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.25M Buy
+66,080
New +$1.04M 0.01% 1842
2025
Q1 		– Sell
-128,248
Closed -$1.79M – 2836
2024
Q4 		$1.79M Buy
+128,248
New +$1.41M 0.01% 1426
2024
Q2 		– Sell
-20,705
Closed -$205K – 2955
2024
Q1 		$205K Sell
20,705
-86,463
-81% -$645K ﹤0.01% 3070
2023
Q4 		$346K Buy
+107,168
New +$291K ﹤0.01% 2720
2023
Q1 		– Sell
-84,022
Closed -$1.24M – 3879
2022
Q4 		$1.24M Buy
84,022
+83,033
+8,396% +$1.45M 0.01% 2248
2022
Q3 		$19K Sell
989
-48,058
-98% -$1.09M ﹤0.01% 4243
2022
Q2 		$1.04M Buy
49,047
+42,478
+647% +$871K 0.01% 2449
2022
Q1 		$127K Sell
6,569
-7,216
-52% -$122K ﹤0.01% 3177
2021
Q4 		$286K Buy
13,785
+12,466
+945% +$248K ﹤0.01% 2827
2021
Q3 		$32K Sell
1,319
-1,303
-50% -$29.7K ﹤0.01% 2865
2021
Q2 		$72K Sell
2,622
-11,147
-81% -$314K ﹤0.01% 2754
2021
Q1 		$398K Buy
13,769
+12,061
+706% +$377K 0.01% 2085
2020
Q4 		$48K Buy
1,708
+301
+21% +$7.37K ﹤0.01% 2468
2020
Q3 		$41K Buy
+1,407
New +$37.6K ﹤0.01% 2378

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cubist Systematic Strategies's ARQT Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Arcutis Biotherapeutics (ARQT) in Q3 2025: 66,080 shares worth $1.25M. The stake represents 0.01% of the portfolio and ranks #1842 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in ARQT as recently as Q4 2024.

Cubist Systematic Strategies first reported a position in ARQT in Q3 2020 and has held it in 14 quarters since. The position peaked at $1.79M in Q4 2024. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • Cubist Systematic Strategies held 66,080 shares of Arcutis Biotherapeutics worth $1.25M as of Q3 2025.
  • Arcutis Biotherapeutics was a new Cubist Systematic Strategies position in Q3 2025.
  • Arcutis Biotherapeutics made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1842 holding.
  • Cubist Systematic Strategies first reported a position in Arcutis Biotherapeutics in Q3 2020 and has held it in 14 quarters since.
  • Cubist Systematic Strategies's Arcutis Biotherapeutics position peaked at $1.79M in Q4 2024.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.